RATIONALE: Intensive care unit (ICU)-acquired weakness is a frequent complication of critical illness. It is unclear whether it is a marker or mediator of poor outcomes. OBJECTIVES: To determine acute outcomes, 1-year mortality, and costs of ICU-acquired weakness among long-stay (≥8 d) ICU patients and to assess the impact of recovery of weakness at ICU discharge. METHODS: Data were prospectively collected during a randomized controlled trial. Impact of weakness on outcomes and costs was analyzed with a one-to-one propensity-score-matching for baseline characteristics, illness severity, and risk factor exposure before assessment. Among weak patients, impact of persistent weakness at ICU discharge on risk of death after 1 year was examined with multivariable Cox proportional hazards analysis. MEASUREMENTS AND MAIN RESULTS:A total of 78.6% were admitted to the surgical ICU; 227 of 415 (55%) long-stayassessable ICU patients were weak; 122 weak patients were matched to 122 not-weak patients. As compared with matched not-weak patients, weak patients had a lower likelihood for live weaning from mechanical ventilation (hazard ratio [HR], 0.709 [0.549-0.888]; P = 0.009), live ICU (HR, 0.698 [0.553-0.861]; P = 0.008) and hospital discharge (HR, 0.680 [0.514-0.871]; P = 0.007). In-hospital costs per patient (+30.5%, +5,443 Euro per patient; P = 0.04) and 1-year mortality (30.6% vs. 17.2%; P = 0.015) were also higher. The 105 of 227 (46%) weak patients not matchable to not-weak patients had even worse prognosis and higher costs. The 1-year risk of death was further increased if weakness persisted and was more severe as compared with recovery of weakness at ICU discharge (P < 0.001). CONCLUSIONS: After careful matching the data suggest that ICU-acquired weakness worsens acute morbidity and increases healthcare-related costs and 1-year mortality. Persistence and severity of weakness at ICU discharge further increased 1-year mortality. Clinical trial registered with www.clinicaltrials.gov (NCT 00512122).
RCT Entities:
RATIONALE: Intensive care unit (ICU)-acquired weakness is a frequent complication of critical illness. It is unclear whether it is a marker or mediator of poor outcomes. OBJECTIVES: To determine acute outcomes, 1-year mortality, and costs of ICU-acquired weakness among long-stay (≥8 d) ICU patients and to assess the impact of recovery of weakness at ICU discharge. METHODS: Data were prospectively collected during a randomized controlled trial. Impact of weakness on outcomes and costs was analyzed with a one-to-one propensity-score-matching for baseline characteristics, illness severity, and risk factor exposure before assessment. Among weak patients, impact of persistent weakness at ICU discharge on risk of death after 1 year was examined with multivariable Cox proportional hazards analysis. MEASUREMENTS AND MAIN RESULTS: A total of 78.6% were admitted to the surgical ICU; 227 of 415 (55%) long-stay assessable ICU patients were weak; 122 weak patients were matched to 122 not-weak patients. As compared with matched not-weak patients, weak patients had a lower likelihood for live weaning from mechanical ventilation (hazard ratio [HR], 0.709 [0.549-0.888]; P = 0.009), live ICU (HR, 0.698 [0.553-0.861]; P = 0.008) and hospital discharge (HR, 0.680 [0.514-0.871]; P = 0.007). In-hospital costs per patient (+30.5%, +5,443 Euro per patient; P = 0.04) and 1-year mortality (30.6% vs. 17.2%; P = 0.015) were also higher. The 105 of 227 (46%) weak patients not matchable to not-weak patients had even worse prognosis and higher costs. The 1-year risk of death was further increased if weakness persisted and was more severe as compared with recovery of weakness at ICU discharge (P < 0.001). CONCLUSIONS: After careful matching the data suggest that ICU-acquired weakness worsens acute morbidity and increases healthcare-related costs and 1-year mortality. Persistence and severity of weakness at ICU discharge further increased 1-year mortality. Clinical trial registered with www.clinicaltrials.gov (NCT 00512122).
Authors: Elizabeth R Pfoh; Amy W Wozniak; Elizabeth Colantuoni; Victor D Dinglas; Pedro A Mendez-Tellez; Carl Shanholtz; Nancy D Ciesla; Peter J Pronovost; Dale M Needham Journal: Intensive Care Med Date: 2016-09-16 Impact factor: 17.440
Authors: Krysta S Wolfe; Bhakti K Patel; Erica L MacKenzie; Shewit P Giovanni; Anne S Pohlman; Matthew M Churpek; Jesse B Hall; John P Kress Journal: Chest Date: 2018-09-11 Impact factor: 9.410
Authors: Kathryn A Radigan; Trevor T Nicholson; Lynn C Welch; Monica Chi; Luciano Amarelle; Martín Angulo; Masahiko Shigemura; Atsuko Shigemura; Constance E Runyan; Luisa Morales-Nebreda; Harris Perlman; Ermelinda Ceco; Emilia Lecuona; Laura A Dada; Alexander V Misharin; Gokhan M Mutlu; Jacob I Sznajder; G R Scott Budinger Journal: J Immunol Date: 2018-12-07 Impact factor: 5.422
Authors: D Clark Files; Amro Ilaiwy; Traci L Parry; Kevin W Gibbs; Chun Liu; James R Bain; Osvaldo Delbono; Michael J Muehlbauer; Monte S Willis Journal: Metabolomics Date: 2016-07-26 Impact factor: 4.290
Authors: Boris Jung; Pierre Henri Moury; Martin Mahul; Audrey de Jong; Fabrice Galia; Albert Prades; Pierre Albaladejo; Gerald Chanques; Nicolas Molinari; Samir Jaber Journal: Intensive Care Med Date: 2015-11-16 Impact factor: 17.440